Avaleht › 2. tüüpi diabeet › Illinois
2. tüüpi diabeet kliinilised uuringud osariigis Illinois
30 uuringut haiguse 2. tüüpi diabeet jaoks otsivad osalejaid osariigis Illinois.
Linnad osariigis Illinois
Ametlik uuringutekst (inglise keeles)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Accellacare - DuPage, Lombard
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT07783802Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
- Endeavor Health, Skokie
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT07817251EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Cedar Crosse Research Center, Chicago
- Accellacare of Duly - Lombard, Lombard
- Accellacare of Duly, Oak Lawn
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Evanston Premier Healthcare Research LLC, Skokie
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Northwestern University, Chicago
- Northshore University Health System, Glenview
VärbamineTerved vabatahtlikud oodatud
Vanused 55 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT06112418A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Cedar Crosse Research Center, Chicago
- Northwestern University, Chicago
- Endeavor Health - Family Medicine Administration, Evanston
- ja veel 1
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Champaign
- Research Site, Chicago
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NorthShore University Health System, Skokie
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Chicago
- Research Site, Melrose Park
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Schaumburg
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- AES - DRS - Synexus Clinical Research US, Inc. - Chicago, Chicago
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 15. sept 2026 · NCT07340320A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
- Cedar-Crosse Research Center, Chicago
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 11. sept 2026 · NCT07415954Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- Research by Design, LLC - Internal Medicine, Chicago
VärbamineFaas 2
Vanused 18–80 · Kõik sood · Uuendatud 11. sept 2026 · NCT07271186A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Melrose Park
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT07662213Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
- Chicago Clinical Research Institute, Chicago
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT07296484A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- SIU Medicine, Springfield
VärbamineFaas 3
Vanused 10–18 · Kõik sood · Uuendatud 9. sept 2026 · NCT07282613A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Research Site, Chicago
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. sept 2026 · NCT07662135AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Elevate Clinical Research, Gurnee
- Chicago Medical Research LLC, Hazel Crest
- Genesis Orthopedics & Sports Medicine, Oak Brook
- ja veel 1
VärbamineFaas 3
Vanused 45 ja vanemad · Kõik sood · Uuendatud 1. sept 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Chicago
- Research Site, Skokie
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 31. aug 2026 · NCT07662109A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
- Research Site, Melrose Park
VärbamineVaatlusuuring
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. aug 2026 · NCT07606066A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
- Research Site, Chicago
VärbamineFaas 1Terved vabatahtlikud oodatud
Vanused 18–75 · Kõik sood · Uuendatud 12. aug 2026 · NCT07024823A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Illinois at Chicago, Chicago
VärbamineFaas 3
Vanused 10–17 · Kõik sood · Uuendatud 7. aug 2026 · NCT06739122Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
- Northwestern University, Chicago
Värbamine
Vanused 14–75 · Kõik sood · Uuendatud 3. aug 2026 · NCT07579702Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
- Northwestern University, Chicago
Värbamine
Vanused 18–75 · Kõik sood · Uuendatud 3. aug 2026 · NCT07521475Achieving Routine Intervention and Screening for Emotional Health
- University of Chicago, Chicago
Värbamine
Vanused 18 ja vanemad · Kõik sood · Uuendatud 8. juuli 2026 · NCT06887049Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes
- Illinois Institute of Technology, Chicago
VärbamineVaatlusuuring
Vanused 18–65 · Kõik sood · Uuendatud 16. juuni 2026 · NCT07650682Exercise and Protein Efficiency in T2D
- Freer Hall - University of Illinois, Urbana
VärbamineTerved vabatahtlikud oodatud
Vanused 65 ja vanemad · Kõik sood · Uuendatud 29. apr 2026 · NCT07477067Enhancing Diabetes Care: Exposome &Amp; Sensors
- University of Illinois - Chicago, Chicago
- University of Illinois College of Nursing, Chicago
VärbamineVaatlusuuring
Vanused 18–65 · Kõik sood · Uuendatud 25. mai 2025 · NCT06989008My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes
- University of Illinois at Chicago, Chicago
VärbamineTerved vabatahtlikud oodatud
Vanused 21–75 · Kõik sood · Uuendatud 5. märts 2025 · NCT05208164RCT Glargine vs NPH for Treatment of DM in Pregnancy
- Loyola University Medical Center, Maywood
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 1. okt 2024 · NCT06619301Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.